Free Trial

Accuray (NASDAQ:ARAY) Given "Sell (E+)" Rating at Weiss Ratings

Accuray logo with Medical background

Key Points

  • Accuray's stock has received a "sell (E+)" rating from Weiss Ratings, with a consensus rating of "Hold" and an average target price of $5.00.
  • Despite the negative rating, Accuray's shares rose by 7.3% recently, trading at $1.69 with a market cap of approximately $189.93 million.
  • The company reported $127.54 million in revenue for the last quarter, slightly above analysts' expectations, but missed earnings per share estimates by $0.02.
  • Interested in Accuray? Here are five stocks we like better.

Accuray (NASDAQ:ARAY - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other equities analysts have also recently issued reports on ARAY. BTIG Research boosted their price objective on Accuray from $4.00 to $5.00 and gave the company a "buy" rating in a report on Thursday, August 14th. Wall Street Zen raised Accuray from a "sell" rating to a "hold" rating in a research report on Saturday, September 13th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $5.00.

Get Our Latest Analysis on ARAY

Accuray Trading Up 7.3%

Shares of Accuray stock traded up $0.12 on Wednesday, reaching $1.69. The company had a trading volume of 507,896 shares, compared to its average volume of 762,200. The firm's 50-day moving average price is $1.54 and its two-hundred day moving average price is $1.50. Accuray has a 1 year low of $1.14 and a 1 year high of $2.95. The company has a debt-to-equity ratio of 1.53, a current ratio of 1.65 and a quick ratio of 0.92. The firm has a market cap of $189.93 million, a price-to-earnings ratio of -84.25 and a beta of 1.31.

Accuray (NASDAQ:ARAY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The medical equipment provider reported $0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.02). Accuray had a negative net margin of 0.35% and a negative return on equity of 4.92%. The business had revenue of $127.54 million for the quarter, compared to analysts' expectations of $123.78 million. Accuray has set its FY 2026 guidance at EPS. As a group, research analysts predict that Accuray will post 0.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Heartland Advisors Inc. grew its stake in Accuray by 11.8% during the 1st quarter. Heartland Advisors Inc. now owns 4,274,750 shares of the medical equipment provider's stock worth $7,652,000 after buying an additional 450,000 shares during the last quarter. Armistice Capital LLC grew its stake in Accuray by 27.6% during the 2nd quarter. Armistice Capital LLC now owns 3,236,000 shares of the medical equipment provider's stock worth $4,433,000 after buying an additional 700,000 shares during the last quarter. Geode Capital Management LLC grew its stake in Accuray by 7.8% during the 2nd quarter. Geode Capital Management LLC now owns 2,421,724 shares of the medical equipment provider's stock worth $3,318,000 after buying an additional 174,703 shares during the last quarter. TENOR CAPITAL MANAGEMENT Co. L.P. purchased a new position in Accuray during the 2nd quarter worth $2,055,000. Finally, Acuitas Investments LLC grew its stake in Accuray by 100.4% during the 1st quarter. Acuitas Investments LLC now owns 1,420,207 shares of the medical equipment provider's stock valued at $2,542,000 after purchasing an additional 711,654 shares during the last quarter. 64.08% of the stock is currently owned by hedge funds and other institutional investors.

About Accuray

(Get Free Report)

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Accuray Right Now?

Before you consider Accuray, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Accuray wasn't on the list.

While Accuray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.